share_log

Insiders At MiMedx Group Sold US$659k Of Stock Potentially Indicating Weakness

Insiders At MiMedx Group Sold US$659k Of Stock Potentially Indicating Weakness

MiMedx集團內部人士出售了65.9萬美元的股票,可能表明股價疲軟。
Simply Wall St ·  11/01 20:45

Despite the fact that MiMedx Group, Inc. (NASDAQ:MDXG) stock rose 17% last week, insiders who sold US$659k worth of stock in the previous 12 months are likely to be better off. Selling at an average price of US$8.02, which is higher than the current price, may have been the best move for these insiders because their investment would have been worth less now than when they sold.

儘管MiMedx集團股票上週上漲了17%,但在過去12個月中賣出價值65.9萬美元股票的內部人士很可能更好。以平均價格8.02美元出售,高於當前價格,可能是這些內部人士的最佳選擇,因爲他們的投資現在的價值比他們出售時更少。

Although we don't think shareholders should simply follow insider transactions, logic dictates you should pay some attention to whether insiders are buying or selling shares.

雖然我們認爲股東不應僅僅跟隨內部人士的交易,但邏輯告訴我們,應該注意內部人士是購買還是出售股票。

The Last 12 Months Of Insider Transactions At MiMedx Group

過去12個月內部交易MiMedx集團的情況

The insider, Ricci Whitlow, made the biggest insider sale in the last 12 months. That single transaction was for US$250k worth of shares at a price of US$8.06 each. While insider selling is a negative, to us, it is more negative if the shares are sold at a lower price. The silver lining is that this sell-down took place above the latest price (US$6.85). So it may not tell us anything about how insiders feel about the current share price.

在過去12個月中,內部人士中Ricci Whitlow進行了最大規模的內部交易。 單筆交易價值25萬美元的股票,每股8.06美元。 儘管內部人士的賣出是負面的,但對我們來說,如果股票以較低價格出售,則更負面。 唯一的好消息是這次股票拋售是在最新價格(6.85美元)之上進行的。 因此,這可能無法告訴我們內部人士對當前股價的感受。

All up, insiders sold more shares in MiMedx Group than they bought, over the last year. The chart below shows insider transactions (by companies and individuals) over the last year. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

總的來說,在過去一年內,MiMedx集團的內部人員賣出的股票比購買的要多。 下面的圖表顯示了過去一年中公司和個人的內部交易。 如果您點擊圖表,可以看到所有個別交易,包括股價、個人和日期!

big
NasdaqCM:MDXG Insider Trading Volume November 1st 2024
納斯達克CM:mimedx內部交易成交量2024年11月1日

For those who like to find hidden gems this free list of small cap companies with recent insider purchasing, could be just the ticket.

對於那些喜歡發現潛力股票的人,可以免費查看最新內部交易股票的小盤公司名單,這可能正是您要找的機會。

Insider Ownership Of MiMedx Group

mimedx集團內部所有權

Many investors like to check how much of a company is owned by insiders. I reckon it's a good sign if insiders own a significant number of shares in the company. Insiders own 1.4% of MiMedx Group shares, worth about US$14m. This level of insider ownership is good but just short of being particularly stand-out. It certainly does suggest a reasonable degree of alignment.

許多投資者喜歡查看公司由內部所有者擁有多少股份。我認爲,如果內部人員在公司中擁有大量股份,這是一個好跡象。內部人員擁有MiMedx集團股份的1.4%,價值約1400萬美元。這種內部人員所有權水平很好,但還不足以引人注目。它確實表明了合理程度的一致性。

So What Does This Data Suggest About MiMedx Group Insiders?

這些數據暗示MiMedx集團內部人員有什麼?

The fact that there have been no MiMedx Group insider transactions recently certainly doesn't bother us. We don't take much encouragement from the transactions by MiMedx Group insiders. But it's good to see that insiders own shares in the company. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing MiMedx Group. For instance, we've identified 3 warning signs for MiMedx Group (2 shouldn't be ignored) you should be aware of.

最近沒有MiMedx集團內部交易的事實確實不會讓我們感到不安。我們對MiMedx集團內部人員的交易並不感到鼓舞。但看到內部人員擁有公司的股份是好事。除了了解正在發生的內部交易,識別面臨MiMedx集團的風險也是有益的。例如,我們已經發現MiMedx集團存在3個警示信號(2個不應被忽視),您應該注意。

Of course MiMedx Group may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

當然,mimedx集團可能不是最佳的股票買入選擇。因此,您可能希望查看這些優質公司的免費收藏。

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

對於本文而言,內部人是指向相關監管機構報告其交易的個人。我們目前僅考慮公開市場交易和直接利益的私人處置,但不包括衍生交易或間接利益。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接與我們聯繫。或者,發送電子郵件至editorial-team @ simplywallst.com。
Simply Wall St的這篇文章是一般性質的。我們僅基於歷史數據和分析師預測提供評論,使用公正的方法,我們的文章並非意在提供財務建議。這並不構成買入或賣出任何股票的建議,並且不考慮您的目標或財務狀況。我們旨在爲您帶來基於基礎數據驅動的長期聚焦分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St對提及的任何股票都沒有持倉。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論